Wearable Device Data Shows Correlation Between Clinical Assessments, Real-world Functional Recovery in Patients with Pulmonary Embolism</h1> <article> <h1>Wearable Device Data Shows Correlation Between Clinical Assessments, Real-world Functional Recovery in Patients with Pulmonary Embolism</h1> <p>tim.hodson — Fri, 09 Oct 2026 21:46:57 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Fri, 10/09/2026 - 16:46</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 6, 2026 — <a href="https://www.penumbrainc.com/">Penumbra, Inc.</a> has announced results from a subset analysis of the landmark <a href="https://www.penumbrainc.com/storm-pe-rct/">STORM-PE</a> randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test. The findings were presented at the recent Vascular InterVentional Advances (VIVA) meeting.</p> <p>STORM-PE RCT assessed patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT) plus anticoagulation compared to anticoagulation alone. Data from the trial showed patients treated with CAVT plus anticoagulation experienced improved right ventricular recovery and achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations)<sup>1</sup> compared to anticoagulation alone.</p> <p>A cohort of the trial patients were discharged with a fitness watch to track a patient’s activity, including actigraphy measures during everyday living. STORM-PE investigators performed a correlation analysis between watch actigraphy (daily total step count, walking bout data, and daily peak steps) and made comparisons to the 6-minute walk test performed at 30- and 90-day follow-up visits.</p> <h4>Data Capture Via Wearable Device</h4> <p>“STORM-PE is the first RCT in pulmonary embolism therapy to incorporate data from a consumer wearable device, representing an important step forward in understanding how office assessed clinical improvements translate into meaningful real-world recovery,” said Robert Lookstein, M.D., MSc, global co principal investigator of the STORM PE RCT and professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai. “This innovation enables the scientific community to determine whether improvements observed during office assessments are reflected in patients’ real-world experiences at home.”</p> <p>Key findings of this subset analysis include:</p> <ul type="disc"><li> <p>Total daily step count, walking bout length, number of walking bouts, walking bout duration and peak 10-minute step count were significantly correlated with 30-day 6-minute walk test performance.</p> </li> <li> <p>Correlations were strongest with temporally matched wearable and clinic data at 30 days and attenuated with 90-day follow up data.</p> </li> <li> <p>Wearable technology provides a complementary measure of functional recovery after PE.</p> </li> </ul><p>“This STORM-PE subset gives us a more complete picture of patient recovery by allowing us to compare data collected in the clinic with information gathered as patients go about their daily lives,” said Rachel Rosovsky, M.D., MPH, global co-principal investigator of the STORM PE RCT, hematologist at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School. “By generating a more comprehensive view of patient outcomes, these findings have the potential not only to advance our understanding of the role of endovascular therapy in PE, but also to help shape the design of future clinical trials.”</p> <p>Complementing the STORM-PE findings, investigators presented a new interim analysis of 1,000 prospective patients from the STRIKE-PE trial, looking at one-year functional outcomes and quality of life for PE patients after CAVT during the 16th Venous Endovascular INterventional Strategies (VEINS) meeting. STRIKE-PE continues to support the safety and effectiveness of CAVT, including short device times and low adverse events, for treating PE. The study also found longer-term functional outcomes and quality of life benefits, including sustained reduced dyspnea, increased walking distance, restored functional status and improved quality of life. STRIKE-PE is a prospective, international, multicenter study evaluating real-world safety, performance and long-term functional and quality-of-life outcomes of CAVT in up to 1,500 patients.</p> <p>“At Penumbra, we are committed to advancing innovations that are supported by rigorous clinical evidence,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “By incorporating consumer wearables into STORM-PE, we have a unique opportunity to evaluate whether the clinical improvements observed in traditional assessments are reflected in patients’ day-to-day recovery at home. Together with emerging data from STRIKE-PE, these findings contribute to a growing body of evidence supporting a significant role for CAVT in the treatment of PE.”</p> <ol><li> <p>STORM-PE was not powered to detect differences in safety</p> </li> </ol><p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/wearable-device-data-shows-correlation-between-clinical-assessments-real-world-functional" data-a2a-title="Wearable Device Data Shows Correlation Between Clinical Assessments, Real-world Functional Recovery in Patients with Pulmonary Embolism"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fwearable-device-data-shows-correlation-between-clinical-assessments-real-world-functional&title=Wearable%20Device%20Data%20Shows%20Correlation%20Between%20Clinical%20Assessments%2C%20Real-world%20Functional%20Recovery%20in%20Patients%20with%20Pulmonary%20Embolism"></a></span> </article> <article> <h1>Bayer Presents Latest Cardiovascular Research at HFSA</h1> <p>tim.hodson — Fri, 09 Oct 2026 17:23:34 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Fri, 10/09/2026 - 12:23</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 8, 2026 – At the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, Bayer announced that latest research from cardiovascular programs would be presented in a late-breaking presentation along with five poster sessions. </p> <p>“The HFSA Annual Scientific Meeting is an ideal platform to raise awareness of the essential role that clinical trials play in advancing cardiovascular disease care,” said Robert Perkins, MD, Vice President CVR, U.S. Medical Affairs. “We look forward to sharing our science with the community and advancing the industry’s mission of potentially improving patient care.” </p> <p>Data from Bayer’s cardiovascular portfolio in heart failure and cardiac amyloidosis will be presented, including late-breaking data for investigational iodine 124 evuzamitide (I 124 evuzamitide) from a Phase III study in patients with suspected cardiac amyloidosis.</p> <h4>The HFSA cardiovascular presentations include:</h4> <p><b>Cardiac Amyloidosis</b> </p> <ul><li><a href="https://eppro02.ativ.me/web/index.php?page=Session&project=HFSA26&id=P3083">124I-Evuzamitide amyloid-targeted PET/CT scan: Potential for detection of early cardiac amyloidosis in a prospective multicenter phase 3 study cohort </a></li> </ul><p><b>Heart Failure</b> </p> <ul><li> <p><a href="https://eppro02.ativ.me/web/index.php?page=Session&project=HFSA26&id=P2036">Factors Associated With Steroidal Mineralocorticoid Receptor Antagonist Use in Newly Diagnosed Heart Failure </a></p> </li> <li> <p><a href="https://eppro02.ativ.me/web/index.php?page=Session&project=HFSA26&id=P2010">Real-world Initiation And Non-persistence Of Steroidal Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure In The United States </a></p> </li> <li> <p><a href="https://eppro02.ativ.me/web/index.php?page=Session&project=HFSA26&id=P2911"> A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)</a></p> </li> <li> <p><a href="https://eppro02.ativ.me/web/index.php?page=Session&project=HFSA26&id=P2914">A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF) </a></p> </li> <li> <p><a href="https://eppro02.ativ.me/web/index.php?page=Session&project=HFSA26&id=P2927">A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF) </a></p> </li> <li> <p> </p> </li> </ul><p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/bayer-presents-latest-cardiovascular-research-hfsa" data-a2a-title="Bayer Presents Latest Cardiovascular Research at HFSA"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fbayer-presents-latest-cardiovascular-research-hfsa&title=Bayer%20Presents%20Latest%20Cardiovascular%20Research%20at%20HFSA"></a></span> </article> <article> <h1>Global Leaders Meet to Discuss Equitable Access to Life-Saving Mechanical Thrombectomy, Acute Stroke Care</h1> <p>tim.hodson — Thu, 08 Oct 2026 20:42:02 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Thu, 10/08/2026 - 15:42</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 8, 2026 — Government officials, global health leaders, clinicians, patient advocates, professional societies and industry partners gathered during United Nations General Assembly week for "From Resolution to Action: Investing in Acute Stroke Care," a convening focused on translating global commitments on stroke into concrete improvements in prevention, acute treatment, rehabilitation and access to care. The September 22 reception was convened through the <a href="https://www.svin.org/">Society of Vascular and Interventional Neurology's</a> (SVIN) Mission Thrombectomy in partnership with the Business Council for International Understanding (BCIU), Philips and Medtronic Neurovascular. </p> <figure role="group" class="align-right"><br /><figcaption>Photo: Society of Vascular and Interventional Neurology</figcaption></figure><p>The event brought together representatives from leading international cardiovascular, stroke, neurointerventional and global neurosurgical organizations, including the American Heart Association (AHA), World Stroke Organization (WSO), World Federation of Interventional and Therapeutic Neuroradiology (WFITN), Society of NeuroInterventional Surgery (SNIS), and International Society for Global Neurosurgery (ISGNS), alongside Ministries of Health and other global health stakeholders. Together, they brought perspectives spanning public health, stroke systems, neurointervention, global neurosurgery, policy, and implementation.</p> <h4><b>From Resolution to Action</b></h4> <p>The gathering came at a pivotal moment for global stroke policy. WHA79.10, adopted by the World Health Assembly in May, represents a landmark global commitment to addressing stroke comprehensively, including prevention, acute care, rehabilitation, and health-system readiness.</p> <p>Importantly, WHA79.10 was championed by the Egyptian Ministry of Health and Population, with support from the Global Stroke Action Coalition (GSAC), a coalition comprising global organizations and industry leaders dedicated to advancing stroke prevention, treatment, rehabilitation, and access to care worldwide. The resolution represents an important example of how governments, professional organizations, patient advocates, and industry can work together to elevate stroke on the global health agenda.</p> <p>The discussion centered on a fundamental challenge: scientific advances have made highly effective stroke treatments possible, including mechanical thrombectomy for large-vessel occlusion, but millions of eligible patients worldwide still cannot access these treatments in time.</p> <h4><b>Strokenomics: Investing in Recovery</b></h4> <p>Dr. Fawaz Al-Mufti, Global Chair, SVIN-Mission Thrombectomy, opened the clinical discussion with <i>"The Clinical and Economic Case for Acute Stroke Treatment,"</i> highlighting the extraordinary effectiveness of mechanical thrombectomy for eligible patients with large-vessel occlusion stroke. </p> <p>Drawing on global data and an economic analysis spanning six countries, Al-Mufti emphasized that investing in access to thrombectomy can represent a fraction of the societal cost associated with stroke-related disability.</p> <p>"We are already paying for stroke," said Al-Mufti. "The question is whether we choose to pay for recovery today or disability for years to come. A timely thrombectomy can offset a lifetime of disability and its associated costs. We need to stop viewing thrombectomy simply as a procedural expense and recognize access to effective stroke treatment as an investment in people, families and national capacity."</p> <h4><b>A Riveting Stroke Story of Resilience</b></h4> <p>The patient perspective was brought into sharp focus by Margaret O'Neil Wheeler, who shared a moving account of resilience and fortitude following a large-vessel-occlusion stroke. Accompanied by her husband, whose prompt recognition and action helped get her to life-saving care in time, Wheeler was reunited at the event with <b>Dr. </b>Fawaz Al-Mufti, who performed her emergency mechanical thrombectomy at Westchester Medical Center. Their reunion put a human face on the numbers, offering a powerful reminder of what timely access to advanced stroke care can mean: not simply survival, but recovery, independence, and the opportunity to return to life after stroke.</p> <h4><b>From Global Advocacy to Global Access</b></h4> <p>Dr. Dileep Yavagal, Founder and Global Chair Emeritus, SVIN-Mission Thrombectomy, followed with <i>"From Global Advocacy to Global Action."</i></p> <p>Yavagal described stroke as a "long neglected pandemic" and emphasized that solving the global access gap requires more than simply building additional thrombectomy centers. Sustainable systems require public and pre-hospital education, government advocacy, technology, financing, trained teams, and implementation strategies tailored to individual countries.</p> <p>"We have crossed the scientific frontier - we know thrombectomy can profoundly alter the course of a devastating stroke," said Yavagal. "The frontier before us now is access."</p> <h4><b>Turning Recognition Into Action</b></h4> <p>The urgency expressed at the convening reflects a broader commitment from SVIN leadership to translate scientific progress and global policy recognition into measurable improvements in stroke care worldwide.</p> <p>Santiago Ortega-Gutierrez, MD, President of the Society of Vascular and Interventional Neurology, framed this as a responsibility for SVIN and the broader stroke community:</p> <p>"Stroke does not respect borders, and access to life-saving treatment should not be determined by where a patient lives. The science is clear, the therapies exist, and the global community has recognized stroke as an urgent health priority. Our responsibility now is to turn that recognition into action. Through Mission Thrombectomy, SVIN is committed to measurable progress in access, treatment, and recovery—with the goal that every eligible patient has a meaningful opportunity to survive stroke without preventable disability."</p> <p>Kaiz Asif, MD, Vice Chair of SVIN–Mission Thrombectomy, focused on the ultimate measure of that progress: whether treatment reaches patients:</p> <p>"Recognition is important, but ultimately our success will be measured by access. Our goal is to translate this global momentum into a simple reality: that more patients, regardless of where they live, can reach life-saving thrombectomy in time."</p> <p>Robin Novakovic-White, MD, President-Elect of the Society of Vascular and Interventional Neurology, emphasized the collaboration required to translate scientific advances into equitable access:</p> <p>"The science has given us the ability to dramatically change the outcome of a devastating stroke. The next challenge is ensuring that this opportunity is not defined by geography or resources. That will require sustained collaboration among clinicians, health systems, governments, and communities to translate what we know into meaningful access for patients worldwide."</p> <h4>Building Systems </h4> <p>Industry partners underscored that innovation must be accompanied by the systems required to deliver treatment.</p> <p>"Innovation alone is not enough. Devices and therapies make a meaningful difference only when patients can reach the right facility, receive timely diagnosis, and be treated by trained teams within an integrated system of care," said Signe Haughton, Senior Director of Medical, Government, & Societal Affairs and Chief of Staff at Medtronic Neurovascular</p> <p>Philips emphasized the role of connected technologies and workflows:</p> <p>"For people experiencing stroke, every minute matters. Better-connected data, technologies, and clinical workflows can help healthcare professionals make timely decisions, support rapid diagnosis and appropriate treatment, and expand access to the right care when patients need it most," said Felipe Basso, Chief Executive Officer, Latin America, Philips.</p> <h4><b>What Implementation Can Look Like</b></h4> <p>Dr. Mohamed Fawzi, Radiology Advisor to the Minister of Health and Population, Ministry of Health and Population, Arab Republic of Egypt, provided a country perspective on building a national stroke system.</p> <p>Egypt's progress includes 206 stroke units and centers, 58 certified through GAHAR, free thrombolysis, reimbursement for thrombectomy, approval of tenecteplase, and a prehospital hotline linking approximately 100 hospitals. A national electronic stroke registry is also being launched, with plans to expand the network to 440 units, strengthen certification, establish a national rehabilitation pathway, and publish national treatment rates and treatment times.</p> <p>The message emerging from the convening was clear: a resolution creates momentum; implementation is what changes outcomes for patients.</p> <p>The science exists. The therapies exist. The opportunity now is to build the systems that ensure every eligible patient - regardless of geography or resources - can reach life-saving stroke treatment in time.</p> <p>To learn more about the meeting, go to <a href="https://www.svin.org/">www.svin.org/</a></p> <p> </p> <p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/global-leaders-meet-discuss-equitable-access-life-saving-mechanical-thrombectomy-acute" data-a2a-title="Global Leaders Meet to Discuss Equitable Access to Life-Saving Mechanical Thrombectomy, Acute Stroke Care"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fglobal-leaders-meet-discuss-equitable-access-life-saving-mechanical-thrombectomy-acute&title=Global%20Leaders%20Meet%20to%20Discuss%20Equitable%20Access%20to%20Life-Saving%20Mechanical%20Thrombectomy%2C%20Acute%20Stroke%20Care"></a></span> </article> <article> <h1>ClearRead Chest Imaging Suite Now Available on RapidAI Platform</h1> <p>tim.hodson — Thu, 08 Oct 2026 14:33:32 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Thu, 10/08/2026 - 09:33</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 6, 2026 — Riverain Technologies has announced that its FDA-cleared ClearRead Chest suite will be available through <a href="https://www.rapidai.com/">RapidAI</a>, via its Rapid Enterprise Platform. The integration expands access to Riverain's advanced lung and cardiac imaging intelligence within RapidAI's connected enterprise platform, helping radiologists identify subtle findings, reduce cognitive burden and move from imaging insight to clinical action with less workflow friction.</p> <p>Designed for chest CTs and X-rays, ClearRead Chest is a cardiothoracic AI suite that helps radiologists detect, characterize and visualize pulmonary nodules, pneumothoraces, and coronary artery calcification (CAC). Riverain's patented vessel and bone suppression technology provides an unobstructed view of the lungs to improve visualization of nodules and other pathology. The suite delivers clinically proven accuracy and time-saving insights within radiologists' existing workflows, helping ease cognitive burden and support more confident decisions.</p> <p>Riverain develops clinically validated cardiothoracic imaging technology designed to help radiologists see, detect, characterize, and report subtle findings more clearly. Integrating ClearRead Chest into RapidAI's connected platform extends the technology into an enterprise environment that unifies imaging intelligence, clinical workflows, and patient management, helping health systems scale AI without adding separate systems or operational complexity.</p> <h4>ClearRead Chest</h4> <p>ClearRead Chest integrates into the Rapid Enterprise Platform, including its Rapid Edge Cloud infrastructure, the Rapid Navigator Pro radiology workflow solution, RapidAI's mobile and web applications, and its AI governance capabilities. The integration will create a secure, interoperable experience across PACS, EHR, and reporting systems, allowing health systems to deploy Riverain's cardiothoracic imaging intelligence while maintaining workflow consistency and enterprise-grade infrastructure.</p> <p>“ClearRead was developed to help radiologists see subtle chest findings more clearly and confidently within the workflows they already rely on every day,” said Steve Worrell, CEO of Riverain Technologies. “By integrating ClearRead Chest into the Rapid Enterprise Platform, we’re expanding access to our advanced chest imaging technology to support earlier detection of leading global killers like lung cancer, and cardiovascular disease and reduce the burden on radiologists facing increasingly complex imaging workloads.”</p> <p>Through the integration, Riverain's ClearRead Chest suite will be available to RapidAI's install base of more than 2,500 hospitals. The collaboration gives Riverain a broader path to scale advanced cardiothoracic imaging intelligence across health systems while allowing customers to access Riverain and RapidAI solutions through one connected workflow.</p> <p>For Riverain, the collaboration advances its mission to reduce delayed cardiothoracic diagnoses by bringing ClearRead Chest to more radiologists within the systems they use every day. For RapidAI, the integration expands its enterprise imaging ecosystem with clinically validated third-party AI for lung and cardiovascular disease, building on its full-body portfolio.</p> <p> </p> <p></p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/clearread-chest-imaging-suite-now-available-rapidai-platform" data-a2a-title="ClearRead Chest Imaging Suite Now Available on RapidAI Platform"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fclearread-chest-imaging-suite-now-available-rapidai-platform&title=ClearRead%20Chest%20Imaging%20Suite%20Now%20Available%20on%20RapidAI%20Platform"></a></span> </article> <article> <h1>Boston Scientific Names New EVP, COO</h1> <p>tim.hodson — Wed, 07 Oct 2026 16:59:12 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Wed, 10/07/2026 - 11:59</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 7, 2026 — <a href="http://www.bostonscientific.com">Boston Scientific Corp.</a> has appointed Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company's global operations, business units and regions.</p> <h4>Boston Scientific Operating Structure</h4> <p>In connection with Fitzgerald's appointment, Boston Scientific will establish three reportable segments* — Interventional Therapies, Rhythm Solutions and MedSurg also effective Jan. 1. As the company continues to grow and expand its portfolio, the structure is designed to enable faster decision making and support strategic allocation of investments across the company's portfolio.</p> <p>"Joe's deep knowledge of our business and markets, strategic leadership and strong track record of execution make him well suited for this role," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "These changes reflect the scale and breadth of our business today and the opportunities ahead. The new operating model will create greater capacity to focus on our long-term growth priorities while enabling our businesses to move faster and remain close to our customers and their patients."</p> <p>Lance Bates, executive vice president and president, Interventional Therapies, will lead the global Interventional Therapies segment, which will include the Penumbra business following the anticipated close of the acquisition. Nick Spadea-Anello, executive vice president and president, Atrial Fibrillation Solutions, will lead the global Rhythm Solutions segment. Stephen Morse, senior vice president and president, Asia Pacific, will serve as executive vice president and president, MedSurg and Asia Pacific. Each will report to Fitzgerald.</p> <p>Fitzgerald currently serves as executive vice president and group president, Cardiovascular, Boston Scientific. Under his leadership, the company has strengthened its portfolio through organic innovation, strategic investments and commercial execution, introducing new technologies that have advanced care for patients around the world.</p> <p><i>*Interventional Therapies will include the Interventional Cardiology, Vascular Therapies and Interventional Oncology & Embolization businesses; Rhythm Solutions will include Electrophysiology, WATCHMAN and Cardiac Rhythm Management & Diagnostics; and MedSurg will include Endoscopy, Urology and Neuromodulation.</i></p> <p> </p> <p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/boston-scientific-names-new-evp-coo" data-a2a-title="Boston Scientific Names New EVP, COO"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fboston-scientific-names-new-evp-coo&title=Boston%20Scientific%20Names%20New%20EVP%2C%20COO"></a></span> </article> <article> <h1>FDA Approves New Capabilities for Abbott's CardioMEMS HF System</h1> <p>tim.hodson — Mon, 05 Oct 2026 21:06:47 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Photo: Abbott</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Mon, 10/05/2026 - 16:06</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 5, 2026 — <a href="http://www.abbott.com">Abbott </a>has announced U.S. Food and Drug Administration (FDA) approval for updates to the <a href="https://www.cardiovascular.abbott/us/en/patients/treatments-therapies/pulmonary-artery-pressure-monitoring-for-heart-failure/managing-heart-failure.html?gad_source=1&gad_campaignid=16451159695&gclid=CjwKCAiAqKbMBhBmEiwAZ3UboFaEK095Qn9oer3ALXwBgreRxKMtXHiqauhimoE3FVFAfby58WoVDBoCy40QAvD_BwE#cmems-video/?utm_source=google&utm_campaign=hf-cardiomems-patient-brand&utm_adgroup=cardiomems-brand&utm_term=cardiomems%20abbott&utm_content=688871405266">CardioMEMS HF System </a>that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones, giving them greater insight into their condition and helping them take a more active role in their care.</p> <p>Heart failure can worsen long before symptoms become noticeable. Pulmonary artery pressure — the pressure of blood flowing from the heart to the lungs — can rise as heart failure worsens, often weeks before patients experience any symptoms. The CardioMEMS HF System, which has been shown to reduce heart failure hospitalizations<sup>2,3</sup> and mortality risk<sup>4,5</sup>, measures pulmonary artery pressure through an implanted sensor in the pulmonary artery. For more than a decade, clinicians have used pulmonary artery pressure readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment.</p> <p>Building on that clinical experience with CardioMEMS, Abbott is continuing to evolve heart failure management with digital tools that help keep clinicians and patients connected between office visits. The CardioMEMS HF System with the CardioGuide HF App represents an important step toward helping patients take an earlier, more active role in understanding and managing their heart failure.</p> <p>"Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop," said Andrew J. Sauer, M.D., cardiologist and vice president for research at Saint Luke's Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City. "By giving patients access to their pressure trends and personalized guidance from their care team, the CardioGuide HF App can help patients better understand their condition, understand why treatment adjustments are recommended, and take a more active role in managing their heart failure."</p> <p>The new CardioMEMS HF System capabilities also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure. Once in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App, ensuring patients receive timely feedback and guidance from their care team.</p> <p>"Abbott is reshaping heart failure care by bringing meaningful, actionable information directly to patients," said Katie Spayde, vice president of Abbott's heart failure division. "For many people living with heart failure, managing their condition is part of everyday life. By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits."</p> <p>Abbott plans to make CardioGuide HF App and Dynamic Treatment Plan available later this year.</p> <p> </p> <ol><li> <p>Abbott. Data on file.</p> </li> <li> <p>Heywood JT, Zalawadiya S, Bourge RC, et al. Sustained reduction in pulmonary artery pressures and hospitalizations during 2 years of ambulatory monitoring. <i>J Card Fail.</i> 2023;29(1):56–66. doi: 10.1016/j.cardfail.2022.10.422.</p> </li> <li> <p>Adamson PB, Abraham WT, Stevenson LW, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. <i>Circ Heart Fail</i>. 2016;9(6):e002600. doi:10.1161/CIRCHEARTFAILURE.115.002600.</p> </li> <li> <p>Lindenfeld J, Costanzo MR, Zile MR, et al., on behalf of the GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators. Meta-Analysis of Implantable Hemodynamic Monitors for HFrEF. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. <i>J Am Coll Cardiol.</i> 2024;83:682-694. doi:10.1016/j.jacc.2023.11.030.</p> </li> <li> <p>Zalawadiya S, Abraham J, Rathman L, et al. Early reduction of pulmonary artery pressures is associated with improved mortality among Medicare beneficiaries with heart failure. <i>JACC Heart Fail.</i> 2025;13(10):102589. doi:10.1016/j.jchf.2025.102589.</p> </li> </ol><p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/fda-approves-new-capabilities-abbotts-cardiomems-hf-system" data-a2a-title="FDA Approves New Capabilities for Abbott's CardioMEMS HF System "><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Ffda-approves-new-capabilities-abbotts-cardiomems-hf-system&title=FDA%C2%A0Approves%20New%20Capabilities%20for%20Abbott%27s%20CardioMEMS%20HF%20System%20"></a></span> </article> <article> <h1>Endologix Debuts New Corporate Brand</h1> <p>tim.hodson — Mon, 05 Oct 2026 15:42:05 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Mon, 10/05/2026 - 10:42</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 5, 2026 – Endologix Holdings, LLC has announced <a href="http://rheveramed.com">Rhevera Medical </a>as its new corporate brand. The new identity reflects the company’s broader commitment to partnering with physicians who treat complex vascular disease and supporting patients whose lives, mobility and independence depend on the company’s technologies.</p> <p>For decades, Endologix has worked alongside physicians who care for patients with serious vascular conditions, including abdominal aortic aneurysms and peripheral arterial disease. As the company has expanded beyond aortic repair into percutaneous bypass and mechanical thrombectomy, its purpose has remained centered on a simple clinical need: to preserve blood flow where it is threatened and restore it where it has been lost.</p> <p>Rhevera Medical brings that purpose forward through a portfolio designed for physicians managing some of the most challenging vascular cases. The company’s technologies include the ALTO Abdominal Stent Graft System, the AFX 2 Endovascular AAA System, the DETOUR System for percutaneous bypass in peripheral arterial disease, and the Pounce Thrombectomy System. Together, these platforms are intended to give physicians meaningful options when conventional approaches may not fully address a patient’s clinical needs.</p> <p>“Our name has changed because the needs of physicians and patients have expanded,” said John Liddicoat, M.D., president and chief executive officer of Rhevera Medical. “Rhevera Medical reflects who we are becoming: a company focused on helping physicians preserve and restore blood flow for patients facing serious vascular disease. Whether a patient is at risk from an aneurysm, threatened by limb ischemia, or experiencing an acute vessel blockage, our work begins with the clinical reality physicians face and the outcomes patients are counting on.”</p> <h4>New Brand Name</h4> <p>Rhevera (reh-VEH-ruh) combines rheo, Greek for flow, and vera, Latin for true. The name expresses the company’s focus on true, sustained blood flow across its therapies and the clinical outcomes physicians and patients seek.</p> <p>“Rhevera Medical represents a clear commitment to the physicians who take on difficult vascular cases and to the patients who need dependable treatment options,” said John Martin, M.D., senior clinical advisor, Vascular Therapies, at Rhevera Medical. “Our goal is to support clinical decision making with technologies that are differentiated, evidence led and built around the realities of patient care.”</p> <p>To learn more about how Rhevera Medical is working with physicians to preserve and restore blood flow for patients with vascular disease, visit <a href="http://rheveramed.com">rheveramed.com</a>.</p> <p> </p> <p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/endologix-debuts-new-corporate-brand" data-a2a-title="Endologix Debuts New Corporate Brand"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fendologix-debuts-new-corporate-brand&title=Endologix%20Debuts%20New%20Corporate%20Brand"></a></span> </article> <article> <h1>FDA Approves Surgical Pulmonary Valve for Pediatric Patients</h1> <p>tim.hodson — Fri, 02 Oct 2026 17:14:28 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Fri, 10/02/2026 - 12:14</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 1, 2026 — <a href="https://www.edwards.com/">Edwards Lifesciences</a> has received U.S. Food and Drug Administration (FDA) approval for its AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed for pediatric patients with congenital heart disease requiring pulmonary valve replacement.</p> <p>For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy, with the ability to be expanded as a child grows. Valve expansion is performed through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. </p> <p>“Children with congenital pulmonary valve disease have long needed prosthetic valves that can account for growth over time,” said Dr. Emile Bacha, surgeon-in-chief at NewYork-Presbyterian/Columbia University Irving Medical Center and a professor of surgery at Columbia University Vagelos College of Physicians and Surgeons who was one of the investigators in the trial. “The AUTUS valve gives congenital heart teams a new way to think about long-term care planning for pediatric patients who may otherwise face multiple surgeries.”</p> <h4>Pediatric Valve Study</h4> <p>FDA approval of the AUTUS valve was based on the totality of clinical evidence from the pivotal study. The study met its primary safety and effectiveness endpoints, with 100% of patients free from device-related complications through 30 days and demonstrating favorable valve performance with no AUTUS valve reinterventions through six months. Among patients who completed one-year follow-up, 100% showed consistent outcomes, demonstrating an RVOT mean gradient of 40 mmHg or less, less than moderate pulmonary regurgitation and no valve reinterventions. Patients will continue to be followed for 10 years. The AUTUS valve previously received FDA Breakthrough Device designation for its potential to address an important unmet need.</p> <p>This approval expands Edwards’ congenital treatment options, which also include SAPIEN 3, the Alterra Adaptive Prestent and pediatric atrioseptostomy catheters. </p> <p>“For decades, Edwards has worked to address the needs of structural heart patients with complex conditions,” said Bernard Zovighian, Edwards’ CEO. “The AUTUS valve represents a meaningful advancement for children who have historically had limited treatment options. Our commitment extends beyond innovation to generating clinical evidence and collaborating with physicians, medical societies and patient groups to help address the evolving needs of patients with congenital heart disease.”</p> <p> </p> <p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/fda-approves-surgical-pulmonary-valve-pediatric-patients" data-a2a-title="FDA Approves Surgical Pulmonary Valve for Pediatric Patients"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Ffda-approves-surgical-pulmonary-valve-pediatric-patients&title=FDA%20Approves%20Surgical%20Pulmonary%20Valve%20for%20Pediatric%20Patients"></a></span> </article> <article> <h1>Gore Begins Pivotal Study in Aortoiliac Aneurysmal Disease</h1> <p>tim.hodson — Thu, 01 Oct 2026 20:14:13 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> <blockquote class="image-field-caption"><p>Gore Excluder Iliac Branch Endoprosthesis. (Photo: W.L. Gore)</p> </blockquote> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Thu, 10/01/2026 - 15:14</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Oct. 1, 2026 — <a href="https://www.goremedical.com/">W. L. Gore & Associates’ medical business (Gore)</a> has announced the first patient enrollment in the IBE Plus Pivotal Study, a clinical trial evaluating the investigational Gore Excluder IBE Plus Stent Graft for the treatment of aortoiliac and common iliac artery aneurysms. The first patients were implanted by Shahab Toursavadkohi, MD, National Principal Investigator at the University of Maryland and Aleem Mirza, MD, Principal Investigator at Orlando Regional Healthcare System.</p> <p>Every year, 200,000 people in the U.S. are diagnosed with an abdominal aortic aneurysm (AAA), with up to 28% of AAAs extending into the iliac arteries. Despite evolving technology, existing iliac branch devices have limitations in their anatomic suitability to treat all patients.<sup>1,2</sup></p> <h4>IBE Plus Pivotal Study</h4> <p>The IBE Plus Clinical Trial is a prospective, nonrandomized, multicenter, interventional trial designed to evaluate the safety and effectiveness of the Gore Excluder IBE Plus Stent Graft in the endovascular treatment of aortoiliac and common iliac artery aneurysms. The study plans to enroll patients in two study arms at approximately 30 sites in the United States, with follow-up through 5 years.</p> <p>“The initiation of this pivotal study is an exciting step forward for patients with aortoiliac aneurysmal disease,” said Shahab Toursavadkohi, MD, National Principal Investigator from the University of Maryland. “Maintaining internal iliac artery perfusion remains a key consideration in treatment planning. This study is an important milestone in the development of treatments to potentially expand iliac branch repair for more patients.”</p> <p>“Aortoiliac aneurysmal disease can present unique treatment planning considerations, making continued clinical research especially important,” said Dr. Mirza. “We are excited to participate in this study and contribute to the clinical evidence being generated.”</p> <h4><strong>Advancing Iliac Branch Innovation</strong></h4> <p>“Clinical research is essential to advancing endovascular treatment options,” said Jill Paine, Product and Innovation Leader at Gore. “Science, engineering, and clinical evidence have long been the foundation of our innovation. The IBE Plus Pivotal Study reflects our ongoing commitment to partner with physicians and address unmet patient needs.”</p> <p>Additional information about the study is available at <a href="https://clinicaltrials.gov/study/NCT07304102">https://clinicaltrials.gov/study/NCT07304102</a></p> <p> </p> <ol><li> <p>Abdominal aortic aneurysm. Society for Vascular Surgery. Accessed July 23, 2026. <a href="https://vascular.org/your-vascular-health/vascular-conditions/common-conditions/abdominal-aortic-aneurysm">https://vascular.org/your-vascular-health/vascular-conditions/common-conditions/abdominal-aortic-aneurysm</a></p> </li> <li> <p>Gouveia E Melo R, Fenelli C, Fernández Prendes C, <em>et al</em>. A cross-sectional study on the anatomic feasibility of iliac side branch grafts in a real-world setting. <em>J Vasc Surg</em>. 2022;76(3):724-732. doi:10.1016/j.jvs.2022.02.056</p> </li> </ol><p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/gore-begins-pivotal-study-aortoiliac-aneurysmal-disease" data-a2a-title="Gore Begins Pivotal Study in Aortoiliac Aneurysmal Disease"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fgore-begins-pivotal-study-aortoiliac-aneurysmal-disease&title=Gore%20Begins%20Pivotal%20Study%20in%20Aortoiliac%20Aneurysmal%20Disease"></a></span> </article> <article> <h1>Survey: Patients Want Home-Based Cardiac Rehab, But Coverage, Clinical Oversight Drive Participation</h1> <p>tim.hodson — Thu, 01 Oct 2026 14:49:16 +0000</p> <div class="field field--name-field-image field--type-image field--label-hidden field--items"> <div class="field--item"> </div> </div> <span><span lang="" about="http://www.dicardiology.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang="">tim.hodson</span></span> <span>Thu, 10/01/2026 - 09:49</span> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Sept. 29, 2026 — <a href="https://www.vivalink.com/">Vivalink</a> has published new results from a new survey <a href="https://www.vivalink.com/what-remote-cardiac-rehab-patients-want">examining patient attitudes</a> toward home-based cardiac rehabilitation and remote patient monitoring (RPM). The findings point to strong demand for more flexible approaches to these rehabilitation programs and highlight the importance of insurance coverage, clinical support and seamless technology in making home-based programs viable for patients.</p> <p>The survey of more than 150 U.S. adults with cardiac conditions found that patients are highly receptive to completing cardiac rehabilitation outside of a traditional hospital or clinic. If a provider recommended a home-based program, 79% of respondents said they would be very or somewhat likely to participate, and when given the choice between in-clinic and home-based options, 68% said they would prefer a primarily home-based or hybrid approach.</p> <p>Interest alone, however, may not be enough to drive participation. When asked to identify their top considerations for participation in home-based care, respondents ranked insurance coverage higher than any other factor measured (58%). Sixty percent indicated they would not pay out of pocket for a home-based program, while 87% said knowing the program was covered by insurance would make them more likely to participate.</p> <p>The findings also suggest that patients want the flexibility of recovering at home without losing connection to their care team. When assessing willingness to participate, patients cited active monitoring and review of data by their providers and having the ability to contact their care team as equally important as having easy-to-use monitoring equipment and flexibility to participate on their own schedule.</p> <h4><b>Key findings from the survey include:</b></h4> <ul type="disc"><li> <p><b>RPM is gaining patient acceptance: </b>Seventy-eight percent of respondents said they would be comfortable using a wearable at home, and 81% were very or somewhat confident that a wearable could accurately capture the information their care team needs.</p> </li> <li> <p><b>Patients want technology to run in the background: </b>Sixty-three percent of respondents cited automatic transmission of health information to care teams, without requiring them to manually record or submit data, as the most important factor for making RPM easy to use. This was followed by device comfort (57%), clear and simple instructions (44%), and little or no setup (37%).</p> </li> <li> <p><b>The biggest concerns about using RPM at home are practical: </b>Among the top concerns for choosing home-based care, lack of motivation to exercise alone emerged as number one (40%), followed by lack of space or equipment at home (37%) and concern about performing exercises correctly (31%), outranking clinical or technological worries.</p> </li> </ul><p>"These findings show that patients value cardiac rehabilitation programs that offer greater convenience and flexibility while still keeping their care team closely connected," said Sam Liu, vice president at Vivalink. "The opportunity is to make RPM simple and unobtrusive while giving clinicians the information they need to stay involved. At the same time, expanding access will require reimbursement models that make home-based care an option patients can realistically participate in."</p> <p>Vivalink's acute RPM solution combines patient-friendly medical wearables with an integrated data platform and clinician portal for continuous remote data collection and monitoring. The solution is also used for other applications such as post-operative atrial fibrillation monitoring at Brigham and Women's Hospital in Boston, Massachusetts, and epilepsy induced cardiac events studies at Ochsner Health in New Orleans, Louisiana, to advance research and care delivery across cardiology and neurology.</p> <p>To download the full survey results, visit <a href="http://www.vivalink.com/what-remote-cardiac-rehab-patients-want">www.vivalink.com/what-remote-cardiac-rehab-patients-want</a>.</p> <p></p><p> </p> </div> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.dicardiology.com/content/survey-patients-want-home-based-cardiac-rehab-coverage-clinical-oversight-drive" data-a2a-title="Survey: Patients Want Home-Based Cardiac Rehab, But Coverage, Clinical Oversight Drive Participation"><hr /><h4 class="share-title">If you enjoy this content, please share it with a colleague</h4><a class="a2a_button_email"></a><a class="a2a_button_facebook"></a><a class="a2a_button_twitter"></a><a class="a2a_button_linkedin"></a><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.dicardiology.com%2Fcontent%2Fsurvey-patients-want-home-based-cardiac-rehab-coverage-clinical-oversight-drive&title=Survey%3A%20Patients%20Want%20Home-Based%20Cardiac%20Rehab%2C%20But%20Coverage%2C%20Clinical%20Oversight%20Drive%20Participation"></a></span> </article> </main></body></html>